Literature DB >> 3097025

The difference in pharmacokinetics of mitomycin C, given either as a single agent or as a part of combination chemotherapy.

J Verweij, M Stuurman, J de Vries, H M Pinedo.   

Abstract

In a previous report it was suggested that the total body clearance of mitomycin C (MMC) was different after single agent treatment compared to combination chemotherapy. This suggestion was based on recalculations to one dose level. In the present study a fixed dose of 10 mg/m2 was used. Seven patients on single agent MMC and eight on combination chemotherapy were studied. Terminal half-life varied from 25 to 78 mm, volume of distribution from 7 to 73 l/m2, total body clearance from 11 to 56 l/h per m2, and area under the plasma concentration-time curve (AUC) from 177 to 933 micrograms/h per l. Total body clearance was significantly higher and AUC significantly lower in patients on combination chemotherapy. The cause of this difference was not investigated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3097025     DOI: 10.1007/bf00395925

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  9 in total

1.  Isolation of new fractions of antitumor mitomycins.

Authors:  S WAKAKI; H MARUMO; K TOMIOKA; G SHIMIZU; E KATO; H KAMADA; S KUDO; Y FUJIMOTO
Journal:  Antibiot Chemother (Northfield)       Date:  1958-05

2.  Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung.

Authors:  R G Buice; H B Niell; P Sidhu; B J Gurley
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

3.  Clinical pharmacokinetics of high-dose mitomycin C.

Authors:  R B Schilcher; J D Young; V Ratanatharathorn; C Karanes; L H Baker
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Recovery from mitomycin C-induced hemolytic uremic syndrome. A case report.

Authors:  J Verwey; E Boven; J van der Meulen; H M Pinedo
Journal:  Cancer       Date:  1984-12-15       Impact factor: 6.860

5.  Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.

Authors:  G A van Hazel; M Scott; J Rubin; C G Moertel; R T Eagan; M J O'Connell; J S Kovach
Journal:  Cancer Treat Rep       Date:  1983-09

6.  Pharmacokinetics of mitomycin C in humans.

Authors:  J den Hartigh; J G McVie; W J van Oort; H M Pinedo
Journal:  Cancer Res       Date:  1983-10       Impact factor: 12.701

7.  Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug metabolism.

Authors:  S Kerpel-Fronius; J Verwey; M Stuurman; B Kanyár; P Lelieveld; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  Mitomycin: ten years after approval for marketing.

Authors:  D C Doll; R B Weiss; B F Issell
Journal:  J Clin Oncol       Date:  1985-02       Impact factor: 44.544

9.  Pharmacokinetics of intraarterial mitomycin C in humans.

Authors:  E Hu; S B Howell
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

  9 in total
  3 in total

1.  Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.

Authors:  D Flieger; A S Hoff; T Sauerbruch; I G Schmidt-Wolf
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

2.  Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase 1 study in patients with advanced gastrointestinal cancer.

Authors:  I F Dennis; J R Ramsay; P Workman; N M Bleehen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Pharmacokinetic study of mitomycin C with emphasis on the influence of aging.

Authors:  T Miya; Y Sasaki; A Karato; N Saijo
Journal:  Jpn J Cancer Res       Date:  1992-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.